Sydney, Australia 18 December 2015 – Clarity Pharmaceuticals, a radiopharmaceutical company focused on the treatment of serious disease, has been awarded a Research Connections Grant under the Entrepreneurs’ Programme.
The grant, valued at $50,000, will go toward funding the employment of Australian scientist Charmaine Jeffery as Preclinical Development Manager, who will be responsible for conducting imaging and biodistribution studies in preclinical models with novel radiopharmaceuticals. Furthermore, Ms Jeffery will be located and will collaborate directly with researchers at the Centre for Advanced Imaging (CAI) at the University of Queensland, a world class imaging facility.
Ms Jeffery has 10 years’ experience as a radiopharmaceutical scientist, producing radiopharmaceuticals to clinical quality control standards. She has been a contributor to radiopharmaceutical research in Australia by developing a program to produce and supply copper-64 to Australian researchers and has performed her own pre-clinical research with copper-64 at the Harry Perkins Institute Australian Cancer Research Facility.
Clarity’s Executive Chairman, Dr Alan Taylor, commented “Charmaine has the exact skill-set we require at Clarity, especially with her unique experience with copper, a key ingredient in Clarity’s technology. This collaboration will facilitate the development of novel radiopharmaceuticals from Clarity’s pipeline of diagnostic and theranostic candidates, as well as novel products from external clients looking to utilise preclinical imaging and biodistribution as a drug development tool.”
“This grant will enhance our already strong collaboration with the University of Queensland, and will provide additional resources toward the translation of novel therapies. It builds on our recently announced Business Growth Grant that once again allows Clarity to further strengthen its experience and capability in radiopharmaceutical development. Furthermore, this grant assists Clarity to recruit a local scientist and imbed them within a world class institute like the CAI, which will allow both groups to expand joint projects, promoting translational science in Australia” said Dr Taylor.
